Articles and Videos
InMed CEO says ‘tremendous potential’ for its cannabinoid-based therapy to treat glaucoma
InMed Pharmaceuticals Inc (CSE:IN) (OTCMKTS:IMLFF) CEO Eric Adams sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. In this interview,...
Source: Proactive Investors
Edison Talks: Interview with Eric Adams, CEO of InMed Pharmaceuticals
In the first episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, discusses InMed’s biosynthesis platform and its pipeline of cannabinoids...
CEO interview: InMed Biosynthesis for Cannabinoid Manufacturing
In this interview, Eric Adams, chief executive officer of InMed Pharmaceuticals provides an overview of InMed’s differentiated biosynthesis platform and its therapeutic pipeline of cannabinoids....
Source: Edison Group
Biosynthesis of Cannabinoids – Producing Cannabinoids Without the Plant!
A biosynthesis platform technology Cannabinoids are closely related compounds that are the active constituents of the cannabis plant. While there are over 100 different cannabinoids, the...
Source: BTV
Reimagining Medicine? Novartis Wraps Pharma’s First Big Global Pot Deal
In a watershed moment for medical cannabis advocates in the United States, Swiss giant Novartis’ $NVS Sandoz AG unit has tied up with Canadian medical...
Source: Endpoints News
The Promise of Cannabinoids to Treat Pain
The focus of treating pain over the last decade has led to the emergence of a number of opioid drugs. Since their introduction, this method...
Source: Money Inc
